Tumor size, stage and grade alterations of urinary peptidome in RCC.
Tumor size, stage and grade alterations of urinary peptidome in RCC.
复制标题
RCC中泌尿肽组的肿瘤大小，阶段和等级改变。
DOI：
10.1186/s12967-015-0693-8
复制
发表时间：
2015-10-20
影响因子：
7.4
通讯作者：
Magni F
中科院分区：
文献类型：
--
作者：
Chinello C;Cazzaniga M;De Sio G;Smith AJ;Grasso A;Rocco B;Signorini S;Grasso M;Bosari S;Zoppis I;Mauri G;Magni F
已经发现了几种有前途的生物标志物用于RCC，但它们中没有一种用于临床实践中预测肿瘤进展。预测肿瘤侵袭性的最广泛使用的特征仍然是癌症的阶段，大小和等级。因此，本研究的目的是研究尿肽组，以寻找和鉴定尿中浓度与肿瘤生长测量和临床数据相关的肽。使用了一种应用于ccRCC尿肽组（n = 117）的蛋白质组学方法，该方法基于用活化磁珠预分级分离，然后进行MALDI-TOF分析。对MS分析获得的尿肽谱进行系统相关性研究。通过LC-ESI-MS/MS获得肽身份。根据肿瘤大小、pT和等级，分别有15、26和5种肽显示其尿浓度的统计学显著性改变。此外，观察到15和9个信号在不同pT或等级值的患者中具有统计学上改变的尿水平，即使在非常早期的阶段。其中，C1 RL、A1 AGx、ZAG 2G、PGBM、MMP 23、GP 162、ADA 19、G3 P、RSPH 3、DREB、NOTC 2、SAFB 2和CC 168被鉴定。我们确定了几种肽，其尿丰度根据肿瘤的大小，阶段和等级而变化。其中，有几种可能在肿瘤的发生、发展和侵袭性中发挥作用。这些结果可能是一个有用的起点，为未来的研究，旨在验证其可能用于RCC患者的管理。本文的在线版本（doi：10.1186/s12967-015-0693-8）包含补充材料，可供授权用户使用。
Several promising biomarkers have been found for RCC, but none of them has been used in clinical practice for predicting tumour progression. The most widely used features for predicting tumour aggressiveness still remain the cancer stage, size and grade. Therefore, the aim of our study is to investigate the urinary peptidome to search and identify peptides whose concentrations in urine are linked to tumour growth measure and clinical data. A proteomic approach applied to ccRCC urinary peptidome (n = 117) based on prefractionation with activated magnetic beads followed by MALDI-TOF profiling was used. A systematic correlation study was performed on urinary peptide profiles obtained from MS analysis. Peptide identity was obtained by LC–ESI–MS/MS. Fifteen, twenty-six and five peptides showed a statistically significant alteration of their urinary concentration according to tumour size, pT and grade, respectively. Furthermore, 15 and 9 signals were observed to have urinary levels statistically modified in patients at different pT or grade values, even at very early stages. Among them, C1RL, A1AGx, ZAG2G, PGBM, MMP23, GP162, ADA19, G3P, RSPH3, DREB, NOTC2 SAFB2 and CC168 were identified. We identified several peptides whose urinary abundance varied according to tumour size, stage and grade. Among them, several play a possible role in tumorigenesis, progression and aggressiveness. These results could be a useful starting point for future studies aimed at verifying their possible use in the managements of RCC patients. The online version of this article (doi:10.1186/s12967-015-0693-8) contains supplementary material, which is available to authorized users.